Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Eli Lilly and Company
Hoffmann-La Roche
Arcus Biosciences, Inc.
Duke University
AstraZeneca
USWM, LLC (dba US WorldMeds)
Poseida Therapeutics, Inc.
AstraZeneca
Amgen
Seagen Inc.
Novartis
City of Hope Medical Center
EMD Serono
University Health Network, Toronto
NeoTX Therapeutics Ltd.
BicycleTx Limited
SystImmune Inc.
Pfizer
TCR2 Therapeutics
TCR2 Therapeutics
Exelixis
Jonsson Comprehensive Cancer Center
Cancer Research UK
Compugen Ltd
Tempus AI
Memorial Sloan Kettering Cancer Center
Agenus Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Revolution Medicines, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Baltimore VA Medical Center
Comprehensive Support Project for Oncology Research
NGM Biopharmaceuticals, Inc
Adaptimmune
ImmunoVaccine Technologies, Inc. (IMV Inc.)